Eikon Therapeutics（EIKN）株式概要エイコン・セラピューティクス社は、米国で臨床バイオ医薬品会社として事業を展開している。 詳細EIKN ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性6/6配当金0/6リスク分析今後3年間の収益は年平均6.4%減少すると予測されている。 収益が 100 万ドル未満 ( $0 )US市場と比較した過去 3 か月間の株価の変動現在は利益が出ておらず、今後3年間で利益が出る見込みはない すべてのリスクチェックを見るEIKN Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW472,568 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA472,568 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$10.33該当なし内在価値ディスカウントEst. Revenue$PastFuture-342m172016201920222025202620282031Revenue US$16.7Earnings US$3.0AdvancedSet Fair ValueView all narrativesEikon Therapeutics, Inc. 競合他社Ovid TherapeuticsSymbol: NasdaqCM:OVIDMarket cap: US$489.0mEvommuneSymbol: NYSE:EVMNMarket cap: US$512.4mRezoluteSymbol: NasdaqCM:RZLTMarket cap: US$479.5mPrelude TherapeuticsSymbol: NasdaqGS:PRLDMarket cap: US$590.2m価格と性能株価の高値、安値、推移の概要Eikon Therapeutics過去の株価現在の株価US$10.3352週高値US$17.4052週安値US$7.90ベータ01ヶ月の変化1.37%3ヶ月変化-22.04%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-31.13%最新ニュースお知らせ • 19hEikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and to the Compensation CommitteeEikon Therapeutics, Inc. appointed Ma. Fatima D. Francisco as an independent director to its Board of Directors, where Ms. Francisco will also serve on the Board’s Compensation Committee. Ms. Francisco most recently served as Chief Executive Officer, Baby, Feminine and Family Care at The Procter & Gamble Company, where she led one of the company's largest global business units. During her more than 35-year career at Procter & Gamble, she has held numerous leadership positions across marketing, innovation, commercial operations, and general management. She also serves on the Board of Directors of HP Inc. and Nestlé S.A., and previously served on the Board of Directors of Organon & Co.お知らせ • Aug 13Eikon Therapeutics Selects Dose For TeLuRide-006 Adaptive Phase 2/3 Trial Of EIK1001 In Advanced MelanomaEikon Therapeutics, Inc. announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in the TeLuRide-006 trial. This decision aligns with a recommendation from an independent DMC following a prespecified analysis of unblinded data. The DMC recommended that the TeLuRide-006 study continue as planned in all other respects. EIK1001 is an investigational, systemically administered dual-agonist of Toll-like receptors 7 and 8 designed to stimulate both innate and adaptive immune responses to malignancy. In Phase 1 trials of EIK1001, single-agent activity was observed in patients with advanced solid tumors. This mechanism may complement the antitumor immune response engendered by PD-(L)1 blockade. TeLuRide-006 (NCT06697301) is a global, multicenter, randomized, double-blind, adaptive Phase 2/3 registrational trial of EIK1001 or placebo, in combination with pembrolizumab, as first-line therapy for participants with advanced cutaneous melanoma.お知らせ • Aug 11Eikon Therapeutics, Inc. Announces Appointment of Johnny Bennett, Ph.D. to Scientific Advisory BoardEikon Therapeutics, Inc. had announced the addition of Johnny Bennett, Ph.D. to its Scientific Advisory Board. Dr. Bennett currently served as Vice President and Head of Discovery Chemistry at Merck Research Laboratories. A native of Scotland, Dr. Johnny Bennett earned his undergraduate and Ph.D. degrees from Heriot-Watt University in Edinburgh before beginning his career with N.V. Organon in the Netherlands in 1997. There, he worked across neuroscience and cardiovascular disease, with his neuroscience research culminating in the discovery of sugammadex (Bridion), the first medicine developed to rapidly reverse neuromuscular blockade following surgery. In recognition of this achievement, he was a co-recipient of both the American Chemical Society Heroes of Chemistry Award and the Royal Society of Chemistry Malcolm Campbell Memorial Award for outstanding contributions to the biological and medical sciences. After relocating to the United States in 2011, Dr. Bennett joined Merck as Senior Director of Discovery Chemistry in West Point before moving to lead the Discovery Chemistry organization at the company’s Boston site in 2012. He had since taken on a series of increasingly broad leadership roles within Merck’s Discovery Chemistry group, and was promoted to Vice President in 2022. Dr. Bennett also served as interim Head of Discovery Oncology in 2024. Earlier in 2026, Dr. Bennett was promoted to his current role of Vice President and Head of Discovery Chemistry. Dr. Bennett joined a distinguished group of scientists serving on the company’s Scientific Advisory Board, including: Eric Betzig, Ph.D., is a co-founder of Eikon, a professor at the University of California, Berkeley, and a 2014 Nobel laureate whose pioneering work in super-resolution microscopy helped provide the technological foundation for Eikon’s proprietary single molecule tracking (SMT) platform. Thomas Cech, Ph.D., is a Distinguished Professor of Biochemistry at the University of Colorado, Boulder and a 1989 Nobel laureate whose research established the ability of certain RNA molecules to behave as enzymes. Trey Ideker, Ph.D., is the Director of the Big Data Institute at the University of Oxford (UK), and a Professor of Medicine at the University of California, San Diego. He is a leader in computational approaches to understanding complex biological processes, including those associated with disease pathogenesis. Robert “Tij” Tjian, Ph.D., is a co-founder of Eikon, a professor of biochemistry, biophysics and structural biology and the Li Ka Shing Chancellor's Chair in Biology at the University of California, Berkeley, and former president of the Howard Hughes Medical Institute. Wendy B. Young, Ph.D., is an accomplished medicinal chemist and drug discovery executive who previously led small-molecule drug discovery research at Genentech and now advises biotechnology companies and serves as an advisor to GV (Google Ventures).お知らせ • Jul 27Eikon Therapeutics Doses First Patient in TeLuRide-008 Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung CancerEikon Therapeutics, Inc. has dosed the first patient in TeLuRide-008, a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC). TeLuRide-008 (NCT07365319) is a global, multicenter, double-blind, placebo-controlled, randomized adaptive Phase 2/3 study to evaluate the clinical activity and safety of EIK1001 administered intravenously in combination with pembrolizumab and histology-appropriate chemotherapy to systemic therapy-naïve participants with Stage 4 non-squamous or squamous NSCLC. The specific chemotherapy for non-squamous histology is pemetrexed plus either carboplatin or cisplatin, while for squamous histology it is carboplatin plus paclitaxel or nab-paclitaxel. The study is being conducted in two phases (Phase 2 and Phase 3) and will be analyzed in three parts (dose optimization, dose expansion and confirmatory hypothesis testing). TeLuRide-008 is the second registrational phase 2/3 trial for EIK1001. TeLuRide-006 (NCT06697301), which is enrolling patients with advanced malignant melanoma, was initiated in May of 2025. EIK1001 is an investigational, systemically administered dual-agonist of Toll-like receptors 7 and 8 designed to stimulate both innate and adaptive immune responses. In Phase 1 trials of EIK1001, single-agent activity was observed in patients with advanced malignancy. This mechanism may complement the antitumor immune response engendered by PD-(L)1 blockade. EIK1001 has been studied in over 500 patients and observed to be well-tolerated to date, both as a monotherapy, and in combination with PD-(L)1-specific antibody-based therapy.Seeking Alpha • Jul 20Eikon Therapeutics: Behind The Rough DebutSummary Eikon Therapeutics trades at a small discount to cash but lacks near-term catalysts and robust clinical data. EIK1001’s NSCLC Phase 2 results showed improved ORR and DCR over SOC, yet market reaction was muted and pivotal data are years away. EIK1003’s efficacy lags approved PARP inhibitors, and anemia rates, while lower, do not offset modest response rates. Read the full article on Seeking AlphaBoard Change • Jul 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Fama Francisco was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.最新情報をもっと見るRecent updatesお知らせ • 19hEikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and to the Compensation CommitteeEikon Therapeutics, Inc. appointed Ma. Fatima D. Francisco as an independent director to its Board of Directors, where Ms. Francisco will also serve on the Board’s Compensation Committee. Ms. Francisco most recently served as Chief Executive Officer, Baby, Feminine and Family Care at The Procter & Gamble Company, where she led one of the company's largest global business units. During her more than 35-year career at Procter & Gamble, she has held numerous leadership positions across marketing, innovation, commercial operations, and general management. She also serves on the Board of Directors of HP Inc. and Nestlé S.A., and previously served on the Board of Directors of Organon & Co.お知らせ • Aug 13Eikon Therapeutics Selects Dose For TeLuRide-006 Adaptive Phase 2/3 Trial Of EIK1001 In Advanced MelanomaEikon Therapeutics, Inc. announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in the TeLuRide-006 trial. This decision aligns with a recommendation from an independent DMC following a prespecified analysis of unblinded data. The DMC recommended that the TeLuRide-006 study continue as planned in all other respects. EIK1001 is an investigational, systemically administered dual-agonist of Toll-like receptors 7 and 8 designed to stimulate both innate and adaptive immune responses to malignancy. In Phase 1 trials of EIK1001, single-agent activity was observed in patients with advanced solid tumors. This mechanism may complement the antitumor immune response engendered by PD-(L)1 blockade. TeLuRide-006 (NCT06697301) is a global, multicenter, randomized, double-blind, adaptive Phase 2/3 registrational trial of EIK1001 or placebo, in combination with pembrolizumab, as first-line therapy for participants with advanced cutaneous melanoma.お知らせ • Aug 11Eikon Therapeutics, Inc. Announces Appointment of Johnny Bennett, Ph.D. to Scientific Advisory BoardEikon Therapeutics, Inc. had announced the addition of Johnny Bennett, Ph.D. to its Scientific Advisory Board. Dr. Bennett currently served as Vice President and Head of Discovery Chemistry at Merck Research Laboratories. A native of Scotland, Dr. Johnny Bennett earned his undergraduate and Ph.D. degrees from Heriot-Watt University in Edinburgh before beginning his career with N.V. Organon in the Netherlands in 1997. There, he worked across neuroscience and cardiovascular disease, with his neuroscience research culminating in the discovery of sugammadex (Bridion), the first medicine developed to rapidly reverse neuromuscular blockade following surgery. In recognition of this achievement, he was a co-recipient of both the American Chemical Society Heroes of Chemistry Award and the Royal Society of Chemistry Malcolm Campbell Memorial Award for outstanding contributions to the biological and medical sciences. After relocating to the United States in 2011, Dr. Bennett joined Merck as Senior Director of Discovery Chemistry in West Point before moving to lead the Discovery Chemistry organization at the company’s Boston site in 2012. He had since taken on a series of increasingly broad leadership roles within Merck’s Discovery Chemistry group, and was promoted to Vice President in 2022. Dr. Bennett also served as interim Head of Discovery Oncology in 2024. Earlier in 2026, Dr. Bennett was promoted to his current role of Vice President and Head of Discovery Chemistry. Dr. Bennett joined a distinguished group of scientists serving on the company’s Scientific Advisory Board, including: Eric Betzig, Ph.D., is a co-founder of Eikon, a professor at the University of California, Berkeley, and a 2014 Nobel laureate whose pioneering work in super-resolution microscopy helped provide the technological foundation for Eikon’s proprietary single molecule tracking (SMT) platform. Thomas Cech, Ph.D., is a Distinguished Professor of Biochemistry at the University of Colorado, Boulder and a 1989 Nobel laureate whose research established the ability of certain RNA molecules to behave as enzymes. Trey Ideker, Ph.D., is the Director of the Big Data Institute at the University of Oxford (UK), and a Professor of Medicine at the University of California, San Diego. He is a leader in computational approaches to understanding complex biological processes, including those associated with disease pathogenesis. Robert “Tij” Tjian, Ph.D., is a co-founder of Eikon, a professor of biochemistry, biophysics and structural biology and the Li Ka Shing Chancellor's Chair in Biology at the University of California, Berkeley, and former president of the Howard Hughes Medical Institute. Wendy B. Young, Ph.D., is an accomplished medicinal chemist and drug discovery executive who previously led small-molecule drug discovery research at Genentech and now advises biotechnology companies and serves as an advisor to GV (Google Ventures).お知らせ • Jul 27Eikon Therapeutics Doses First Patient in TeLuRide-008 Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung CancerEikon Therapeutics, Inc. has dosed the first patient in TeLuRide-008, a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC). TeLuRide-008 (NCT07365319) is a global, multicenter, double-blind, placebo-controlled, randomized adaptive Phase 2/3 study to evaluate the clinical activity and safety of EIK1001 administered intravenously in combination with pembrolizumab and histology-appropriate chemotherapy to systemic therapy-naïve participants with Stage 4 non-squamous or squamous NSCLC. The specific chemotherapy for non-squamous histology is pemetrexed plus either carboplatin or cisplatin, while for squamous histology it is carboplatin plus paclitaxel or nab-paclitaxel. The study is being conducted in two phases (Phase 2 and Phase 3) and will be analyzed in three parts (dose optimization, dose expansion and confirmatory hypothesis testing). TeLuRide-008 is the second registrational phase 2/3 trial for EIK1001. TeLuRide-006 (NCT06697301), which is enrolling patients with advanced malignant melanoma, was initiated in May of 2025. EIK1001 is an investigational, systemically administered dual-agonist of Toll-like receptors 7 and 8 designed to stimulate both innate and adaptive immune responses. In Phase 1 trials of EIK1001, single-agent activity was observed in patients with advanced malignancy. This mechanism may complement the antitumor immune response engendered by PD-(L)1 blockade. EIK1001 has been studied in over 500 patients and observed to be well-tolerated to date, both as a monotherapy, and in combination with PD-(L)1-specific antibody-based therapy.Seeking Alpha • Jul 20Eikon Therapeutics: Behind The Rough DebutSummary Eikon Therapeutics trades at a small discount to cash but lacks near-term catalysts and robust clinical data. EIK1001’s NSCLC Phase 2 results showed improved ORR and DCR over SOC, yet market reaction was muted and pivotal data are years away. EIK1003’s efficacy lags approved PARP inhibitors, and anemia rates, while lower, do not offset modest response rates. Read the full article on Seeking AlphaBoard Change • Jul 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Fama Francisco was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Jun 09Eikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and Compensation Committee Member, Effective June 15, 2026Eikon Therapeutics, Inc. announced the appointment of Ma. Fatima D. Francisco as an independent director to Eikon’s Board of Directors, effective June 15, 2026. Ms. Francisco will also serve on the Compensation Committee of the Board. Ms. Francisco most recently served as Chief Executive Officer, Baby, Feminine and Family Care at The Procter & Gamble Company, where she led one of the company's largest global business units. During her more than 35-year career at Procter & Gamble, she has held numerous leadership positions across marketing, innovation, commercial operations and general management. She also serves on the Board of Directors of HP Inc. and Nestle S.A., and previously served on the Board of Directors of Organon & Co. Ms. Francisco holds a Bachelor of Science degree in Business Administration and Marketing from the University of the Philippines.New Risk • Mar 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$235m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$235m free cash flow). Earnings are forecast to decline by an average of 6.8% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$456m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).Recent Insider Transactions • Feb 09Independent Director recently bought US$2.0m worth of stockOn the 4th of February, Kenneth Frazier bought around 111k shares on-market at roughly US$18.00 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.お知らせ • Feb 05Eikon Therapeutics, Inc. has completed an IPO in the amount of $381.1968 million.Eikon Therapeutics, Inc. has completed an IPO in the amount of $381.1968 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 21,177,600 Price\Range: $18 Discount Per Security: $1.26 Transaction Features: Sponsor Backed Offering株主還元EIKNUS BiotechsUS 市場7D12.2%2.5%1.7%1Yn/a37.4%20.0%株主還元を見る業界別リターン: EIKNがUS Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: EIKN US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is EIKN's price volatile compared to industry and market?EIKN volatilityEIKN Average Weekly Movement12.0%Biotechs Industry Average Movement10.1%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.1%安定した株価: EIKNの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: EIKNの weekly volatility ( 12% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2019384Roger Perlmuttereikontx.comEikon Therapeutics, Inc.は、米国で臨床バイオ医薬品企業として事業を展開している。深刻なアンメット・メディカル・ニーズに対応する医薬品を開発しています。同社の製品には、自然免疫と適応免疫の抗腫瘍反応を活性化するように設計された全身投与型のTLR 7/8デュアルアゴニストであるEIK1001、卵巣がん、乳がん、前立腺がん、膵臓がんにおける選択的PARP1阻害剤であるEIK1003およびEIK1004、特に脳浸透因子を有するEIK1004が含まれる；脳転移および原発性脳悪性腫瘍に対処するEIK1004、強力なWRNヘリカーゼ阻害剤でありMSI高値腫瘍に対する抗腫瘍剤であるEIK1005、および臨床候補でありアンドロゲン受容体の臨床的に出現した複数の変異体に対する活性を有する次世代アンドロゲン受容体拮抗剤であるEIK1006である。同社は2019年に法人化され、カリフォルニア州ミルブレーを拠点としている。もっと見るEikon Therapeutics, Inc. 基礎のまとめEikon Therapeutics の収益と売上を時価総額と比較するとどうか。EIKN 基礎統計学時価総額US$564.12m収益（TTM）-US$342.06m売上高(TTM)n/a0.0xP/Sレシオ-1.6xPER（株価収益率EIKN は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計EIKN 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$342.06m収益-US$342.06m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-6.32グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%EIKN の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/13 19:34終値2026/08/13 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Eikon Therapeutics, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Jason ZemanskyBofA Global ResearchImogen MansfieldCantor Fitzgerald & Co.Lut Ming ChengJ.P. Morgan3 その他のアナリストを表示
お知らせ • 19hEikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and to the Compensation CommitteeEikon Therapeutics, Inc. appointed Ma. Fatima D. Francisco as an independent director to its Board of Directors, where Ms. Francisco will also serve on the Board’s Compensation Committee. Ms. Francisco most recently served as Chief Executive Officer, Baby, Feminine and Family Care at The Procter & Gamble Company, where she led one of the company's largest global business units. During her more than 35-year career at Procter & Gamble, she has held numerous leadership positions across marketing, innovation, commercial operations, and general management. She also serves on the Board of Directors of HP Inc. and Nestlé S.A., and previously served on the Board of Directors of Organon & Co.
お知らせ • Aug 13Eikon Therapeutics Selects Dose For TeLuRide-006 Adaptive Phase 2/3 Trial Of EIK1001 In Advanced MelanomaEikon Therapeutics, Inc. announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in the TeLuRide-006 trial. This decision aligns with a recommendation from an independent DMC following a prespecified analysis of unblinded data. The DMC recommended that the TeLuRide-006 study continue as planned in all other respects. EIK1001 is an investigational, systemically administered dual-agonist of Toll-like receptors 7 and 8 designed to stimulate both innate and adaptive immune responses to malignancy. In Phase 1 trials of EIK1001, single-agent activity was observed in patients with advanced solid tumors. This mechanism may complement the antitumor immune response engendered by PD-(L)1 blockade. TeLuRide-006 (NCT06697301) is a global, multicenter, randomized, double-blind, adaptive Phase 2/3 registrational trial of EIK1001 or placebo, in combination with pembrolizumab, as first-line therapy for participants with advanced cutaneous melanoma.
お知らせ • Aug 11Eikon Therapeutics, Inc. Announces Appointment of Johnny Bennett, Ph.D. to Scientific Advisory BoardEikon Therapeutics, Inc. had announced the addition of Johnny Bennett, Ph.D. to its Scientific Advisory Board. Dr. Bennett currently served as Vice President and Head of Discovery Chemistry at Merck Research Laboratories. A native of Scotland, Dr. Johnny Bennett earned his undergraduate and Ph.D. degrees from Heriot-Watt University in Edinburgh before beginning his career with N.V. Organon in the Netherlands in 1997. There, he worked across neuroscience and cardiovascular disease, with his neuroscience research culminating in the discovery of sugammadex (Bridion), the first medicine developed to rapidly reverse neuromuscular blockade following surgery. In recognition of this achievement, he was a co-recipient of both the American Chemical Society Heroes of Chemistry Award and the Royal Society of Chemistry Malcolm Campbell Memorial Award for outstanding contributions to the biological and medical sciences. After relocating to the United States in 2011, Dr. Bennett joined Merck as Senior Director of Discovery Chemistry in West Point before moving to lead the Discovery Chemistry organization at the company’s Boston site in 2012. He had since taken on a series of increasingly broad leadership roles within Merck’s Discovery Chemistry group, and was promoted to Vice President in 2022. Dr. Bennett also served as interim Head of Discovery Oncology in 2024. Earlier in 2026, Dr. Bennett was promoted to his current role of Vice President and Head of Discovery Chemistry. Dr. Bennett joined a distinguished group of scientists serving on the company’s Scientific Advisory Board, including: Eric Betzig, Ph.D., is a co-founder of Eikon, a professor at the University of California, Berkeley, and a 2014 Nobel laureate whose pioneering work in super-resolution microscopy helped provide the technological foundation for Eikon’s proprietary single molecule tracking (SMT) platform. Thomas Cech, Ph.D., is a Distinguished Professor of Biochemistry at the University of Colorado, Boulder and a 1989 Nobel laureate whose research established the ability of certain RNA molecules to behave as enzymes. Trey Ideker, Ph.D., is the Director of the Big Data Institute at the University of Oxford (UK), and a Professor of Medicine at the University of California, San Diego. He is a leader in computational approaches to understanding complex biological processes, including those associated with disease pathogenesis. Robert “Tij” Tjian, Ph.D., is a co-founder of Eikon, a professor of biochemistry, biophysics and structural biology and the Li Ka Shing Chancellor's Chair in Biology at the University of California, Berkeley, and former president of the Howard Hughes Medical Institute. Wendy B. Young, Ph.D., is an accomplished medicinal chemist and drug discovery executive who previously led small-molecule drug discovery research at Genentech and now advises biotechnology companies and serves as an advisor to GV (Google Ventures).
お知らせ • Jul 27Eikon Therapeutics Doses First Patient in TeLuRide-008 Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung CancerEikon Therapeutics, Inc. has dosed the first patient in TeLuRide-008, a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC). TeLuRide-008 (NCT07365319) is a global, multicenter, double-blind, placebo-controlled, randomized adaptive Phase 2/3 study to evaluate the clinical activity and safety of EIK1001 administered intravenously in combination with pembrolizumab and histology-appropriate chemotherapy to systemic therapy-naïve participants with Stage 4 non-squamous or squamous NSCLC. The specific chemotherapy for non-squamous histology is pemetrexed plus either carboplatin or cisplatin, while for squamous histology it is carboplatin plus paclitaxel or nab-paclitaxel. The study is being conducted in two phases (Phase 2 and Phase 3) and will be analyzed in three parts (dose optimization, dose expansion and confirmatory hypothesis testing). TeLuRide-008 is the second registrational phase 2/3 trial for EIK1001. TeLuRide-006 (NCT06697301), which is enrolling patients with advanced malignant melanoma, was initiated in May of 2025. EIK1001 is an investigational, systemically administered dual-agonist of Toll-like receptors 7 and 8 designed to stimulate both innate and adaptive immune responses. In Phase 1 trials of EIK1001, single-agent activity was observed in patients with advanced malignancy. This mechanism may complement the antitumor immune response engendered by PD-(L)1 blockade. EIK1001 has been studied in over 500 patients and observed to be well-tolerated to date, both as a monotherapy, and in combination with PD-(L)1-specific antibody-based therapy.
Seeking Alpha • Jul 20Eikon Therapeutics: Behind The Rough DebutSummary Eikon Therapeutics trades at a small discount to cash but lacks near-term catalysts and robust clinical data. EIK1001’s NSCLC Phase 2 results showed improved ORR and DCR over SOC, yet market reaction was muted and pivotal data are years away. EIK1003’s efficacy lags approved PARP inhibitors, and anemia rates, while lower, do not offset modest response rates. Read the full article on Seeking Alpha
Board Change • Jul 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Fama Francisco was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • 19hEikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and to the Compensation CommitteeEikon Therapeutics, Inc. appointed Ma. Fatima D. Francisco as an independent director to its Board of Directors, where Ms. Francisco will also serve on the Board’s Compensation Committee. Ms. Francisco most recently served as Chief Executive Officer, Baby, Feminine and Family Care at The Procter & Gamble Company, where she led one of the company's largest global business units. During her more than 35-year career at Procter & Gamble, she has held numerous leadership positions across marketing, innovation, commercial operations, and general management. She also serves on the Board of Directors of HP Inc. and Nestlé S.A., and previously served on the Board of Directors of Organon & Co.
お知らせ • Aug 13Eikon Therapeutics Selects Dose For TeLuRide-006 Adaptive Phase 2/3 Trial Of EIK1001 In Advanced MelanomaEikon Therapeutics, Inc. announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in the TeLuRide-006 trial. This decision aligns with a recommendation from an independent DMC following a prespecified analysis of unblinded data. The DMC recommended that the TeLuRide-006 study continue as planned in all other respects. EIK1001 is an investigational, systemically administered dual-agonist of Toll-like receptors 7 and 8 designed to stimulate both innate and adaptive immune responses to malignancy. In Phase 1 trials of EIK1001, single-agent activity was observed in patients with advanced solid tumors. This mechanism may complement the antitumor immune response engendered by PD-(L)1 blockade. TeLuRide-006 (NCT06697301) is a global, multicenter, randomized, double-blind, adaptive Phase 2/3 registrational trial of EIK1001 or placebo, in combination with pembrolizumab, as first-line therapy for participants with advanced cutaneous melanoma.
お知らせ • Aug 11Eikon Therapeutics, Inc. Announces Appointment of Johnny Bennett, Ph.D. to Scientific Advisory BoardEikon Therapeutics, Inc. had announced the addition of Johnny Bennett, Ph.D. to its Scientific Advisory Board. Dr. Bennett currently served as Vice President and Head of Discovery Chemistry at Merck Research Laboratories. A native of Scotland, Dr. Johnny Bennett earned his undergraduate and Ph.D. degrees from Heriot-Watt University in Edinburgh before beginning his career with N.V. Organon in the Netherlands in 1997. There, he worked across neuroscience and cardiovascular disease, with his neuroscience research culminating in the discovery of sugammadex (Bridion), the first medicine developed to rapidly reverse neuromuscular blockade following surgery. In recognition of this achievement, he was a co-recipient of both the American Chemical Society Heroes of Chemistry Award and the Royal Society of Chemistry Malcolm Campbell Memorial Award for outstanding contributions to the biological and medical sciences. After relocating to the United States in 2011, Dr. Bennett joined Merck as Senior Director of Discovery Chemistry in West Point before moving to lead the Discovery Chemistry organization at the company’s Boston site in 2012. He had since taken on a series of increasingly broad leadership roles within Merck’s Discovery Chemistry group, and was promoted to Vice President in 2022. Dr. Bennett also served as interim Head of Discovery Oncology in 2024. Earlier in 2026, Dr. Bennett was promoted to his current role of Vice President and Head of Discovery Chemistry. Dr. Bennett joined a distinguished group of scientists serving on the company’s Scientific Advisory Board, including: Eric Betzig, Ph.D., is a co-founder of Eikon, a professor at the University of California, Berkeley, and a 2014 Nobel laureate whose pioneering work in super-resolution microscopy helped provide the technological foundation for Eikon’s proprietary single molecule tracking (SMT) platform. Thomas Cech, Ph.D., is a Distinguished Professor of Biochemistry at the University of Colorado, Boulder and a 1989 Nobel laureate whose research established the ability of certain RNA molecules to behave as enzymes. Trey Ideker, Ph.D., is the Director of the Big Data Institute at the University of Oxford (UK), and a Professor of Medicine at the University of California, San Diego. He is a leader in computational approaches to understanding complex biological processes, including those associated with disease pathogenesis. Robert “Tij” Tjian, Ph.D., is a co-founder of Eikon, a professor of biochemistry, biophysics and structural biology and the Li Ka Shing Chancellor's Chair in Biology at the University of California, Berkeley, and former president of the Howard Hughes Medical Institute. Wendy B. Young, Ph.D., is an accomplished medicinal chemist and drug discovery executive who previously led small-molecule drug discovery research at Genentech and now advises biotechnology companies and serves as an advisor to GV (Google Ventures).
お知らせ • Jul 27Eikon Therapeutics Doses First Patient in TeLuRide-008 Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung CancerEikon Therapeutics, Inc. has dosed the first patient in TeLuRide-008, a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropriate chemotherapy as first-line therapy for treatment-naïve patients with stage 4 Non-Small Cell Lung Cancer (NSCLC). TeLuRide-008 (NCT07365319) is a global, multicenter, double-blind, placebo-controlled, randomized adaptive Phase 2/3 study to evaluate the clinical activity and safety of EIK1001 administered intravenously in combination with pembrolizumab and histology-appropriate chemotherapy to systemic therapy-naïve participants with Stage 4 non-squamous or squamous NSCLC. The specific chemotherapy for non-squamous histology is pemetrexed plus either carboplatin or cisplatin, while for squamous histology it is carboplatin plus paclitaxel or nab-paclitaxel. The study is being conducted in two phases (Phase 2 and Phase 3) and will be analyzed in three parts (dose optimization, dose expansion and confirmatory hypothesis testing). TeLuRide-008 is the second registrational phase 2/3 trial for EIK1001. TeLuRide-006 (NCT06697301), which is enrolling patients with advanced malignant melanoma, was initiated in May of 2025. EIK1001 is an investigational, systemically administered dual-agonist of Toll-like receptors 7 and 8 designed to stimulate both innate and adaptive immune responses. In Phase 1 trials of EIK1001, single-agent activity was observed in patients with advanced malignancy. This mechanism may complement the antitumor immune response engendered by PD-(L)1 blockade. EIK1001 has been studied in over 500 patients and observed to be well-tolerated to date, both as a monotherapy, and in combination with PD-(L)1-specific antibody-based therapy.
Seeking Alpha • Jul 20Eikon Therapeutics: Behind The Rough DebutSummary Eikon Therapeutics trades at a small discount to cash but lacks near-term catalysts and robust clinical data. EIK1001’s NSCLC Phase 2 results showed improved ORR and DCR over SOC, yet market reaction was muted and pivotal data are years away. EIK1003’s efficacy lags approved PARP inhibitors, and anemia rates, while lower, do not offset modest response rates. Read the full article on Seeking Alpha
Board Change • Jul 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Fama Francisco was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Jun 09Eikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and Compensation Committee Member, Effective June 15, 2026Eikon Therapeutics, Inc. announced the appointment of Ma. Fatima D. Francisco as an independent director to Eikon’s Board of Directors, effective June 15, 2026. Ms. Francisco will also serve on the Compensation Committee of the Board. Ms. Francisco most recently served as Chief Executive Officer, Baby, Feminine and Family Care at The Procter & Gamble Company, where she led one of the company's largest global business units. During her more than 35-year career at Procter & Gamble, she has held numerous leadership positions across marketing, innovation, commercial operations and general management. She also serves on the Board of Directors of HP Inc. and Nestle S.A., and previously served on the Board of Directors of Organon & Co. Ms. Francisco holds a Bachelor of Science degree in Business Administration and Marketing from the University of the Philippines.
New Risk • Mar 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$235m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$235m free cash flow). Earnings are forecast to decline by an average of 6.8% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$456m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change).
Recent Insider Transactions • Feb 09Independent Director recently bought US$2.0m worth of stockOn the 4th of February, Kenneth Frazier bought around 111k shares on-market at roughly US$18.00 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
お知らせ • Feb 05Eikon Therapeutics, Inc. has completed an IPO in the amount of $381.1968 million.Eikon Therapeutics, Inc. has completed an IPO in the amount of $381.1968 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 21,177,600 Price\Range: $18 Discount Per Security: $1.26 Transaction Features: Sponsor Backed Offering
